Antibody Validation for Reproducible Protein Data: A Reagent Guide to Antibodies, Cell Lines & ELISAs
Antibody validation is a reagent problem before it is a methods problem — irreproducible protein data usually traces back to the reagents behind it, so the fix starts with what you choose. This guide maps the validation evidence reviewers now expect onto three reagent classes, and shows how BioHippo's validated antibodies, authenticated cell lines, and complete assay kits supply every control in one place. For each product, it says plainly why it's there and whether you actually need it.
Why antibody validation is really a reagent problem
In a survey of 1,576 researchers, more than 70% reported having tried and failed to reproduce another scientist's experiment5. Research antibodies are the workhorse of protein biology, yet they are among the least standardized reagents in the lab. Writing in Nature, Bradbury and Plückthun estimated that poorly defined antibodies cost US researchers around $350 million a year, and argued that binding reagents should be defined by their sequence and produced recombinantly1. The problem has since been measured directly: the YCharOS consortium assessed 614 commercial antibodies against 65 targets using knockout-controlled assays, and found that more than half failed in one or more applications — while recombinant antibodies outperformed monoclonal and polyclonal reagents2. And the antibody is only one link: the cell line it is tested in and the assay used to confirm the result carry their own reproducibility risks. The field has responded by moving from trusting a datasheet to demonstrating specificity and consistency in your own system. Journals now routinely request catalog numbers, clone identities, RRIDs, and the control experiments that show a reported signal is real.
The three sections below — Antibodies, Cell Lines, and ELISA Kits — each open with what reviewers look for from that reagent, then list in-stock BioHippo products with a one-line reason for each. Read the labels: some of these belong on every bench, and some are only there to show you a pattern to copy for your own protein. The larger point is that whatever your target, BioHippo carries validated reagents across all three classes — so you can assemble a figure's worth of controls without chasing five different suppliers. Browse the full ranges of antibodies, cell lines, and ELISA kits.
The five antibody validation pillars reviewers reference
Most current guidance traces back to a community framework of five conceptual validation strategies3. You do not need all five for every experiment — but you should be able to name which pillar your evidence comes from.
| Validation pillar | What it demonstrates |
|---|---|
| Genetic strategy | Signal is lost when the target gene is knocked out or knocked down (CRISPR KO, siRNA/shRNA, Cre-lox). The strongest evidence of specificity. |
| Orthogonal strategy | Antibody-based signal correlates with an antibody-independent method (e.g. mass spectrometry, RNA-seq, quantitative ELISA). |
| Independent antibody | Two antibodies raised against different epitopes of the same target give concordant results. |
| Tagged / recombinant expression | Signal tracks with expression of a tagged or recombinant form of the target protein. |
| Immunocapture + MS | The antibody pulls down its intended target, confirmed by mass spectrometry of the captured protein. |
The validation controls reviewers ask for by name
| Control | What it rules out | Supplied by |
|---|---|---|
| Positive control | That your antibody detects the target at all — a recombinant antigen or overexpression lysate gives defined signal at the expected size. | Recombinant proteins · expression-host cells |
| Genetic / negative control | That the band or stain is the target, not background — a knockout/knockdown sample should lose the signal. | KO/knockdown or Cre-lox cell systems |
| Isotype control | Non-specific binding driven by isotype/Fc, especially in flow and IHC/IF. | Matched-isotype IgG |
| Secondary-only control | Signal from the secondary antibody or detection system alone. | Secondary antibodies |
| Loading control | That lane differences reflect biology, not unequal loading. | Housekeeping antibodies |
| Orthogonal confirmation | That an independent method agrees with the antibody-based result. | Quantitative ELISA |
Antibodies
Two very different kinds of reagent live in this section, and confusing them is the most common mistake. Some antibodies you keep on the bench for every Western blot, whatever you study — the loading and secondary-only controls. Others are specific to the one protein you actually work on — your target primary and its positive control. Below, the first group is labeled Bench staple and the second Worked example, shown with a single target (uPAR) so you can copy the pattern for yours.
Why listed: every quantitative blot needs one housekeeping band to prove lanes were loaded equally — otherwise a change in your target could just be a pipetting difference. Pick one per gel; you need these no matter what you study. A recombinant clone (below) gives the most consistent lot-to-lot signal.
Why listed: run one lane (or well) with the secondary but no primary to be sure your bands aren't coming from the detection system itself. Match the secondary to the host species of your primary — anti-rabbit for a rabbit primary, anti-mouse for a mouse primary. Every WB and ELISA lab keeps both.
Why listed: for the protein you actually study you need two things — an antibody to detect it, and a positive control to prove that antibody works. Neither is universal; you buy them for your target. We show one target, uPAR, purely as the pattern. If you don't study uPAR, these two exact items aren't for you — buy the equivalent pair for your protein. Where a recombinant monoclonal exists for your target, prefer it: a sequence-defined clone gives consistent lots.
Do you really need the recombinant protein? Not always. A known-positive cell lysate does the same job more cheaply and shows the native protein. Buy the recombinant when you want a defined, unambiguous reference band or a quantitation standard — and note tagged recombinants can run at a slightly different size than the endogenous protein.
Cell Lines
The cells you validate in are a reproducibility variable in their own right — and, usefully, they let you make controls instead of buying a different one for every target. Each line below is listed for a specific job.
Why listed: transfect this line with your target and its lysate becomes a positive control; the untransfected cells are the matched negative. Because it works for any target, it's the general-purpose alternative to buying a separate recombinant antigen for every protein you study — one vial supports many projects.
When you need it: any time cell identity underpins your result — you report findings in a named line, compare across labs or passages, or a reviewer could ask "is that really the cell you think it is?" Misidentified and cross-contaminated lines are a top cause of irreproducible work4, and journals increasingly ask for authentication (STR profiling) and mycoplasma status.
What to buy: don't default to GM12878 — that was only our example. Choose the authenticated line that matches your tissue, disease, and species. BioHippo's authenticated catalog spans the common models; a few below show the range. Buy the one that is your model system.
When you need it: the genetic control — where signal disappears once the gene is removed or silenced — is the strongest specificity evidence there is. Reach for it when you validate a new or poorly characterized antibody, report a novel target, or make a knockout/knockdown phenotype central to your story. It's the control reviewers rank highest for a key target antibody.
What to buy — three routes, depending on your setup:
Quick pick: if a knockdown line already exists for your gene, Route 1 is fastest; if not, Route 2 lets you build a knockout in a standard host; Route 3 is for labs already working in floxed/Cre-lox models.
ELISA Kits
ELISA appears here for one reason: orthogonal confirmation. A reviewer trusts your Western blot far more when a second, independent method agrees. A quantitative ELISA measures the same protein across the same samples so you can show the trend matches your blot — strongest for secreted or soluble targets you can read in supernatant, serum, or lysate.
When you need it: to orthogonally confirm a soluble or secreted target. What to buy: the complete kit for your analyte and species — pre-coated plate, standards, and buffers all included, nothing to assemble. The targets below are only examples of the format; the catalog covers hundreds of analytes across human, mouse, and rat.
Pre-submission antibody validation checklist
Run before you write the methods section- Antibody identity is fully cited: vendor, catalog number, clone, lot, and RRID.
- Validation is shown in the same application (WB / IHC / IF / IP / flow) as your reported data.
- A positive control — recombinant antigen or overexpression lysate — produces signal at the expected size.
- At least one specificity control is included; genetic (KO/knockdown/Cre-lox) is strongest.
- Isotype and/or secondary-only controls are included for flow and imaging.
- A loading/normalization control is shown for every quantitative blot.
- Cell lines are authenticated and mycoplasma-tested; identity and passage are recorded.
- Where feasible, an orthogonal method (ELISA, MS, or RNA-seq) corroborates the result.
- Antibody concentration and lot number are logged so the result can be reproduced.
Frequently asked questions
Yes — it's a normal practice. You load a small amount, usually a few nanograms, of the recombinant version of your target in its own lane. Because you know exactly what it is, it should give a band at the expected size. If your antibody detects that lane but nothing in your samples, the antibody works and your samples are genuinely negative. If it detects neither, the problem is the antibody or the detection system, not your biology.
A single vial goes a long way, since you only load nanogram amounts. The same protein also doubles as the standard curve for quantitative blots and ELISAs.
A lysate from a cell line known to express your protein does the same job, costs less, and shows the native protein. Many labs use exactly this.
Buy the recombinant when you want an unambiguous reference band or an absolute quantitation standard. One caveat: recombinant proteins often carry tags (His, GST, Fc) and may lack glycosylation, so they can run at a different size than the endogenous protein. Predict the size from the construct, not from the native protein.
Both things are true. A sandwich ELISA traps your protein between a capture antibody that coats the plate and a detection antibody that produces the signal. Those two must bind different, non-overlapping spots on the protein. That pair is simply how the assay works.
But in a complete kit the pair is already built in and the plate comes pre-coated. You buy one kit, run it, done. You only handle the antibodies yourself if you deliberately choose a build-your-own antibody-pair format, which most people never need.
It's a sample known to contain your target, run alongside your unknowns to prove the antibody and the whole detection chain are working. If it gives signal as expected, then a negative result in your real sample means “target absent,” not “assay failed.”
What you use depends on the technique: a known-positive lysate or recombinant antigen for Western blot; a cell population known to express the marker for flow cytometry; a known-positive control tissue for IHC/IF; the kit calibrator for ELISA. Run it under identical conditions — same antibody lot, dilution, incubation, and detection — as your samples.
They do different jobs. A CRISPR knockout removes the protein completely, so if a band still appears at the right size, that band is definitely not your protein. This is the cleaner specificity control.
An shRNA knockdown only lowers the protein — some always remains. So you can say the band got weaker, never that it disappeared. That makes it weaker evidence of specificity, but it is the right tool when removing the protein entirely would kill the cells, or when you want to study graded loss of function.
Partly. A knockout control in another cell line is real evidence that the antibody recognises your target protein — that property travels, which is why published validation data is genuinely useful.
What does not travel is whether the antibody is clean in your cells. Extra bands depend on what else a cell line happens to express, so an antibody can look perfect in one line and show a cross-reacting band in another. To claim that a specific band in your blot is your protein, the comparison lane must be your own cells, unedited. The two lanes you compare should differ in one thing only: the gene.
Check before you commit. A knockout only works as a control because you compare it against a parental lane that shows a band. If the parental line never made your protein, both lanes come out blank and you have learned nothing.
Checking is quick and free: DepMap/CCLE and the Human Protein Atlas both list which proteins each named cell line expresses. Confirm with qPCR or mass spectrometry if you want to be certain. Mass spectrometry has the advantage of being antibody-independent, so it does not reintroduce circular reasoning.
You must prove the knockout really is a knockout by sequencing the edited gene, or by qPCR for a knockdown — and not by using the very antibody you are testing. If you use the antibody to decide the cells are knockout, then use those cells to prove the antibody works, you have proved nothing. This is why large validation efforts build their knockout lines on genetic confirmation rather than antibody signal2.
Not automatically. Validation does not transfer between applications — a clone that performs well in Western blot may fail in immunoprecipitation or immunofluorescence, and large-scale testing has found exactly this pattern2. Show validation in the same application, and ideally the same species and sample type, as the data you report.
Pick one whose size is clearly separated from your target so the bands do not overlap — GAPDH runs around 36 kDa, β-actin around 42 kDa, and β-tubulin around 55 kDa. Then confirm that your experimental treatment does not change its expression; housekeeping proteins are not invariant under every condition. A recombinant clone gives the most consistent signal from lot to lot.
A recombinant antibody is produced from a cloned, sequence-defined DNA construct rather than from an animal or a hybridoma. That gives you the same molecule in every batch, so lot-to-lot variation largely disappears, and the reagent cannot be lost when an animal or hybridoma dies. A polyclonal, by contrast, is defined by an animal, so every bleed differs.
References
The figures and frameworks cited in this note come from the following sources.
- Bradbury, A. & Plückthun, A. Reproducibility: standardize antibodies used in research. Nature 518, 27–29 (2015). doi:10.1038/518027a · PMID: 25652980Source of the ~$350 million annual cost figure and the case for sequence-defined recombinant antibodies.
- Ayoubi, R. et al. Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications. eLife 12, e91645 (2023). doi:10.7554/eLife.91645 · YCharOS study (PMID 37398479)The YCharOS study: 614 antibodies, 65 targets, knockout-controlled — more than half failed in one or more tests, performance varied between WB/IP/IF, and recombinant antibodies outperformed monoclonal or polyclonal reagents.
- Uhlén, M. et al. A proposal for validation of antibodies. Nature Methods 13, 823–827 (2016). doi:10.1038/nmeth.3995 · PMID: 27595404The International Working Group for Antibody Validation framework — the five validation pillars, applied application-specifically.
- Capes-Davis, A. et al. Check your cultures! A list of cross-contaminated or misidentified cell lines. International Journal of Cancer 127, 1–8 (2010). doi:10.1002/ijc.25242 · PMID: 20143388 · ICLAC Register of Misidentified Cell LinesCell line misidentification and cross-contamination; the ICLAC register continues to grow as new compromised lines are confirmed.
- Baker, M. 1,500 scientists lift the lid on reproducibility. Nature 533, 452–454 (2016). doi:10.1038/533452a · PMID: 27225100Survey context: of 1,576 researchers, more than 70% have failed to reproduce another scientist's experiment.
The take-home
One validated toolkit for reproducible antibody data.
Validated recombinant antibodies with matched loading and secondary controls, authenticated and knockdown cell lines, recombinant antigen standards, and complete ELISA kits — all in stock and research-ready. Whatever your target, you can source every antibody validation control for a publication-ready figure from a single supplier.
Explore validated reagents at ebiohippo.comFor Research Use Only. Not for use in diagnostic or therapeutic procedures. Product availability, pricing, and specifications are current as of publication and subject to change; confirm details on the linked product pages. Target/clone pairings shown as validation examples do not imply a pre-packaged kit. © BioHippo.
